Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $49 price target.
March 28, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences and maintained a $49 price target.
The reiteration of an Overweight rating and the maintenance of a $49 price target by a reputable analyst could signal confidence in Harmony Biosciences' future performance, potentially influencing investor sentiment positively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100